Objective: Patients receiving cancer treatments commonly experience haematological adverse effects (AEs) related to chemotherapy or molecularly targeted therapies, which may be associated with ...

Cemiplimab plus chemotherapy showed efficacy and consistent safety in advanced penile cancer in the phase 2 EPIC trial.

First-line cemiplimab and platinum-based chemotherapy appears to be safe and effective for patients with advanced penile carcinoma.

Third-line enfortumab vedotin improved outcomes in metastatic urothelial carcinoma, per real-world data from the EV-301 trial ...

The pCR was 37.3% (95% CI, 33.2-41.6) in the durvalumab arm and 27.5% (95% CI, 23.8-31.6) in the comparator arm.

3 While PD-1 and PD-L1 inhibitors combined with chemotherapy significantly improved survival in ES-SCLC, they were also linked to an increased risk of immune-related AEs (imAEs). Compared with ...

SAN FRANCISCO -- A combination of cemiplimab (Libtayo) and standard-of-care chemotherapy appeared to be effective in patients ...

“In most patients we can identify the beginning of AEs and stop the drug which avoids significant events. Used properly, I ...

The same was true of immune-related AEs, as a total of 28 additional grade ... and are associated with poor outcomes when treated with chemotherapy plus targeted agents, Andre noted in discussing ...